Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹69.60
0.60 (0.87%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹248 Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
N/A
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹44.1+57.8%
52W High₹125.5-44.5%
Current Price
₹69.60
Circuit Limits (10%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹62.64
Upper Circuit₹76.56
Reference Price
₹69.60
Investment Checklist
Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹94.63
Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹92.65
10/20 Bullish Cross detected 3 day(s) ago
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
SuperTrend(7,3): Price above SuperTrend (Responsive Setting (Day Trading/Short-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
45%
Trend
NEUTRAL
NEUTRAL
Mixed MA signals — sideways/transition
EMA20
63.49
EMA50
61.37
EMA200
75.34
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows6
Lower Highs4
Lower Lows3
Support & Resistance Levels
Resistance (Above)
₹73.00
₹79.06
₹84.70
₹86.90
₹91.58
Support (Below)
₹67.91
₹64.00
₹61.99
₹61.25
₹57.00
Volume Analysis
TrendINCREASING
Change+303.10%
Unusual VolumeNo
Recent MA Crossovers
10/20 Bullish Cross
3 days ago
BUY
Recent Price Gaps
Gap Up
3 days ago • 1.36%(Filled)
BULLISH
Stop Loss Levels
Fixed Risk
1% Risk₹68.90
3% Risk₹67.51
5% Risk₹66.12
7% Risk (Custom)
₹64.73Technical Levels
1x ATR (Volatility)₹65.45
2x ATR (Swing)₹61.30
3x ATR (Trend)₹57.15
Immediate Support₹67.91
Moving Averages
EMA 9 (Short-term)₹66.21
EMA 20 (Medium-term)₹63.49
EMA 50 (Trend)₹61.37
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹28.5 Cr | ₹33 Cr | ₹36.7 Cr | ₹30.7 Cr |
| Net Profit | ₹1.8 Cr | ₹93,26,000 | ₹-3.4 Cr | ₹-3,000 |
| EPS | — | ₹0.25 | ₹-0.94 | ₹0.00 |
| Operating Profit | ₹4.7 Cr | ₹4.3 Cr | ₹-1.4 Cr | ₹2.8 Cr |
ROE
7.74%
ROCE
9.32%
Debt/Equity
0.37
Current Ratio
1.45
OPM
9.15%
NPM
-0.00%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 01 Aug 2024 | Annual General Meeting | AGM |
| 21 Jul 2023 | Annual General Meeting | AGM |
| 21 Jul 2022 | Annual General Meeting | AGM |
| 22 Jul 2021 | Annual General Meeting | AGM |
| 16 Sept 2020 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for LYKALABS
View AllNEWS
negative
Business Standard - Markets 18d ago
Lyka Labs reports consolidated net loss of Rs 7.61 crore in the March 2026 quarter
Sales decline 16.15% to Rs 28.03 crore
LYKALABSHealthcare
negative
ET Markets - Industry 24d ago
NCLAT allows Lyka Labs appeal; asks Modi Lifecare to pay Rs 63 lakh or face insolvency proceedings
The NCLAT has ruled in favor of Lyka Labs. It overturned a previous NCLT decision. Modi Lifecare Industries must now pay Rs 63 lakh within 30 days. Failure to pay will lead to insolvency proceedings against the company. The tribunal found that Modi Lifecare acknowledged its debt. This ruling stems from unpaid royalties under a technical guidance agreement.
LYKALABSHealthcare